Mazdutide Interactions: Alcohol, Caffeine, Food and Other Compounds

Mazdutide (IBI362) is a once-weekly peptide that activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. A 2025 Drugs review of its first approval reported that mazdutide received approval in China as a GLP-1/glucagon receptor dual agonist for chronic weight management and for type 2 diabetes (PMID 41028652). A 2025 Peptides review placed it within a broader group of multifunctional incretin peptides under development for type 2 diabetes, obesity and associated co-morbidities (PMID 40081498).

Because mazdutide is newer than the single-agonist GLP-1 drugs, the question of how it behaves alongside alcohol, caffeine, food timing or other compounds is asked far more often than it has been studied. This page describes what the peer-reviewed sources listed at the end actually examined, and states plainly where no interaction study exists. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, combination or health decision.

Why "Interaction" Means Two Different Things Here

In pharmacology, an interaction claim can rest on one of two very different foundations:

• Measured interaction data — a study that co-administered two substances and reported what happened to drug levels, glucose, tolerability or an endpoint.
• Mechanistic reasoning — an inference drawn from what a drug is known to do at its receptors, without any experiment testing that specific pairing.

For mazdutide, the verified reviews summarised below described its receptor pharmacology, efficacy and adverse-event profile rather than dedicated co-administration studies; a 2026 Endocrine Reviews overview of novel GLP-1-based medications for type 2 diabetes and obesity discussed the class and its agents without reporting alcohol or caffeine interaction trials for mazdutide (PMID 41054801). Where this page uses mechanistic reasoning, it is labelled as such and is not a finding.

Mazdutide and Alcohol: What the Literature Covers

No study in the verified set co-administered alcohol with mazdutide, and the 2025 first-approval review reported the approval, mechanism and development background without describing any alcohol interaction assessment (PMID 41028652). Likewise, a 2025 systematic review of emerging pharmacotherapies for obesity summarised efficacy and safety across agents rather than alcohol co-exposure (PMID 39952695).

The mechanistic reasoning researchers apply (not a study finding)

Two receptor pathways are usually invoked when researchers discuss alcohol alongside a GLP-1/glucagon co-agonist. First, GLP-1 receptor agonism slows gastric emptying and reduces appetite, mechanisms described for the class in a 2025 Journal of Obesity review of GLP-1 receptor agonists for obesity treatment (PMID 41333115); a slower-emptying stomach is the reason authors reason about altered timing of any orally ingested substance. Second, glucagon receptor agonism engages hepatic metabolism and energy expenditure, pathways reviewed in a 2026 IUPHAR review on repurposing glucagon for obesity and type 2 diabetes (PMID 41478576). Because the liver is central to both glucagon signalling and ethanol metabolism, this is where mechanistic speculation concentrates — but none of these papers tested the pairing, and inference is not evidence.

Mazdutide and Caffeine: What the Literature Covers

No caffeine co-administration study for mazdutide appears in the verified literature. The 2026 network meta-analysis of GLP-1-based drugs for weight loss in adults with overweight or obesity without diabetes compared agents against one another and against placebo, and reported efficacy and safety outcomes rather than stimulant co-exposure (PMID 42688617).

The mechanistic reasoning researchers apply (not a study finding)

Discussion of caffeine alongside incretin-based drugs generally turns on overlapping gastrointestinal effects rather than a shared metabolic pathway, because nausea and related gastrointestinal complaints were the dominant tolerability signal reported for GLP-1-based agents in the 2026 network meta-analysis (PMID 42688617). Whether caffeine measurably changes that profile with mazdutide has not been reported in any paper cited here.

Food, Meals and Fasting

Food is the one "interaction" topic where mazdutide has a substantial evidence base, because reducing energy intake is part of how the drug is understood to work. The 2025 Journal of Obesity review described appetite suppression, delayed gastric emptying and reduced food intake as central mechanisms of GLP-1 receptor agonism in obesity treatment (PMID 41333115). The glucagon component adds a distinct arm: the 2026 IUPHAR review reported that glucagon receptor activation is being harnessed for its effects on hepatic metabolism and energy expenditure alongside GLP-1-driven appetite reduction (PMID 41478576).

On outcomes, the 2026 network meta-analysis compared GLP-1-based drugs for weight loss in adults with overweight or obesity and without diabetes across randomised controlled trials (PMID 42688617), and a 2026 Lancet Diabetes & Endocrinology review described benefits of obesity medications extending beyond weight loss to multiple organ systems (PMID 42208956). None of these papers reported a comparison of fasted versus fed administration windows or a structured fasting protocol combined with mazdutide, so claims about timing relative to meals are not drawn from the studies listed here.

Other Compounds and Medications

Oral medications

The most frequently discussed theoretical interaction for any incretin drug involves oral medicines, because gastric emptying determines how quickly an oral dose reaches the intestine for absorption — a mechanism reviewed for the GLP-1 class in 2025 (PMID 41333115). This is mechanistic reasoning applied to the class; the verified sources on this page did not report pharmacokinetic co-administration studies pairing mazdutide with specific oral drugs.

Glucose-lowering therapy

Mazdutide is used in diabetes as well as obesity settings, and the first-approval review reported its approval in China for type 2 diabetes in addition to chronic weight management (PMID 41028652). A 2025 Frontiers in Endocrinology case report described dose-escalated mazdutide in an adolescent with obesity, type 2 diabetes and hyperuricaemia, and reported on efficacy and safety in that single patient (PMID 41030857). A single case report is the weakest form of clinical evidence and cannot establish how combinations behave across a population.

Other anti-obesity agents and hormone-based drugs

A 2024 review in the Indian Journal of Endocrinology and Metabolism surveyed approved and emerging hormone-based anti-obesity medications as separate therapeutic options (PMID 39676791), and the 2025 systematic review of emerging obesity pharmacotherapies likewise compared agents rather than evaluating them in combination with one another (PMID 39952695). No study in the verified set reported mazdutide combined with another incretin-based drug.

Supplements, nootropics and "stacks"

No paper cited on this page examined mazdutide alongside dietary supplements, herbal products, nootropics or other research peptides. The absence of a study is not a finding in either direction — it simply means the pairing has not been measured in the literature summarised here (PMID 41054801).

Evidence Status at a Glance

Gastrointestinal Tolerability and Adverse Events: What Studies Report

Interaction questions matter largely because they intersect with tolerability. The 2026 network meta-analysis of randomised controlled trials of GLP-1-based drugs for weight loss in adults with overweight or obesity and without diabetes reported adverse events alongside efficacy, with gastrointestinal complaints the characteristic issue for the class (PMID 42688617). The 2025 systematic review of emerging obesity pharmacotherapies similarly reported safety alongside efficacy across the agents it assessed (PMID 39952695), and the 2026 Endocrine Reviews overview discussed the safety considerations that accompany newer GLP-1-based medications (PMID 41054801). For mazdutide specifically, the first-approval review summarised the clinical development programme underpinning its authorisation, including safety data (PMID 41028652), and the adolescent case report described both efficacy and safety observations in that individual (PMID 41030857).

How to Read Interaction Claims Critically

1. Ask what was co-administered. If a source describes only receptor mechanisms, it is reasoning, not measurement — the 2026 IUPHAR glucagon review, for example, examined glucagon biology rather than drug pairings (PMID 41478576).
2. Separate class findings from molecule findings. Findings summarised across GLP-1-based drugs (PMID 42688617) do not automatically transfer to a dual GLP-1/glucagon agonist.
3. Weight the study design. A case report (PMID 41030857) describes one person; a review of hormone-based anti-obesity medications synthesises many (PMID 39676791).
4. Note what endpoints were measured. A review focused on multisystem benefits of obesity medications addressed organ-level outcomes rather than co-exposure pharmacokinetics (PMID 42208956).

Related Reading

For background on the molecule itself — receptor pharmacology, regulatory status and trial programme — see the mazdutide overview.

References

• Mazdutide: First Approval (Drugs, 2025)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon (Journal of Obesity, 2025)
• Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities (Peptides, 2025)
• Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia (Frontiers in Endocrinology, 2025)
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
• IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes (Pharmacological Research, 2026)
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials (BMJ Medicine, 2026)